



Contact:

David Waldman or Justyna Gudaszevska
Crescendo Communications, LLC
Email: mmd@crescendo-ir.com
Tel: (+48) 71 79 11 551

Milestone Medical Appoints Steven F. Robins as President

LIVINGSTON, NJ, December 16, 2014 -- Milestone Medical Inc. (WAR:MMD) today announced the appointment of Steven F. Robins as President of Milestone Medical. Mr. Robins has an extensive background in the healthcare industry and has been working with Milestone Medical on a consulting basis since August of this year. Mr. Robins has held both general management and marketing positions at BAUSCH & LOMB, Johnson & Johnson and Pfizer.

Prior to joining Milestone Medical, Mr. Robins was Chief Marketing Officer of BAUSCH + LOMB where he reversed declines in the flagship Vision Care division and contributed to the successful sale of Valeant Rx at approximately three times revenue. Previously, Mr. Robins was President of BAUSCH & LOMB Vision Care, North America where he oversaw commercial operations. He was instrumental in restoring the division's topline growth in its largest geographic region while substantially increasing EBITDA and gaining market share across the over-the-counter portfolio of products. Prior to Bausch & Lomb Mr. Robins was a Vice President and General Manager of Johnson & Johnson's Consumer Healthcare Business unit in Canada where he was responsible for successfully integrating key Pfizer consumer brands into J&J's portfolio. At Pfizer Consumer Healthcare, Mr. Robins held a series of roles including Group Marketing Director Upper Respiratory where he grew sales and profits in the Benadryl and Sudafed franchises during a time of significant regulatory challenges.

Leonard Osser, Chief Executive Officer of Milestone Medical, commented, "Having demonstrated his skills during his career and since coming on board as a consultant to Milestone earlier this year, I am very pleased to announce Steve's new role as President of Milestone Medical. His business and marketing acumen combined with his leadership skills and team building ability will be integral to Milestone's next phase of growth as we embark upon rolling out our epidural and intra-articular instruments to the global marketplace in the coming months and years."

Mr. Robins commented, "During my four months as a consultant to the company, I have had an inside look at company operations and the market potential for Milestone's epidural and intra-articular instruments. The benefits to both patients and medical practitioners are significant and I look forward to getting the message out to the medical community and driving sales."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. Milestone Medical, Inc. received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2013. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

###